ONCS VS IDRA
Post from YMB by Gold
I would appreciate if someone can clarify the following two things:
1) While going through the data presented by ONCS this morning , I am having difficult to understand how the accelerated approval can be obtained without completing the enrollment of Ph-3 portion of the study for the same refractory patient population ? Do they have the Ph-3 already planned ? I don't think so.
2) How do you compare ONCS ORR 24% out of 21 patients vs IDRA presented 30%ORR out of 34 patients ? and Ph-3 is way ahead and will finish the enrollment by end of this year 2019.
Thank you very much for taking time to respond.